<DOC>
	<DOCNO>NCT00166387</DOCNO>
	<brief_summary>Several non-genetic genetic factor could influence risk inhibitor development hemophilia A discuss fully explore . The aim HIGS identify genetic factor .</brief_summary>
	<brief_title>Hemophilia Inhibitor Genetics Study ( HIGS )</brief_title>
	<detailed_description>The objective HIGS determine host genetic factor , mutation within factor VIII gene , associate development inhibitor severe hemophilia A response antigenic challenge factor VIII . The study involve three phase , enrol family group compose brother pairs parent ( Phase I ) sibling , family group compose person severe hemophilia parent ( Phase II ) , group unrelated people severe hemophilia purpose confirm association identify Phases I II .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>Severe hemophilia A defined baseline factor VIII level &lt; 1 % . A history inhibitor define ever Bethesda titer &gt; 1 BU . Phase I . Subjects hemophilia eligible Phase I study follow apply : An informed consent form , approve appropriate IRB/IEC , administer , sign , date . The subject severe hemophilia A . The subject history inhibitor subject history inhibitor least 100 exposure day factor VIII product . Sufficient documentation exist identify subject 's maximum lifetime Bethesda titer . The subject history inhibitor one full brother severe hemophilia A , without inhibitor , eligible agree study , two parent agree study subject history inhibitor one full brother severe hemophilia A history inhibitor eligible agree study , two parent agree study . Subjects without hemophilia eligible Phase I study follow apply : An informed consent form , approve appropriate IRB/IEC , administer , sign , date . The subject parent ( mother father ) , full sibling , subject hemophilia eligible Phase I study . Phase II . Subjects hemophilia eligible Phase II study follow apply : An informed consent form , approve appropriate IRB/IEC , administer , sign , date . The subject severe hemophilia A . The subject history inhibitor two parent agree study . Sufficient documentation exist identify subject 's maximum lifetime Bethesda titer . Subjects without hemophilia eligible Phase II study follow apply : An informed consent form , approve appropriate IRB/IEC , administer , sign , date . The subject parent ( mother father ) subject hemophilia eligible Phase II study . Phase I . Subjects ( without hemophilia ) exclude participation Phase I : The minimum family group , define pair full brother hemophilia , either concordant ( ) discordant ( one , one without ) inhibitor , parent , enrol . Phase II . Subjects exclude participation Phase II : The minimum family group , define person hemophilia history inhibitor mother father , enrol .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Hemophilia</keyword>
	<keyword>Inhibitors</keyword>
</DOC>